middle.news
How Will Anteris’ $320M Capital Boost Fuel Its DurAVR THV Pivotal Trial?
9:32am on Friday 27th of February, 2026 AEDT
•
Healthcare
Read Story
How Will Anteris’ $320M Capital Boost Fuel Its DurAVR THV Pivotal Trial?
9:32am on Friday 27th of February, 2026 AEDT
Key Points
2025 net loss of $94.2 million on $1.9 million revenue
29% revenue decline due to transition in product sales
Initiation of global pivotal PARADIGM Trial with FDA and European approvals
Raised $230 million in public offering and $90 million from Medtronic private placement
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ANTERIS TECHNOLOGIES GLOBAL (ASX:AVR)
OPEN ARTICLE